Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydrocortisone Plus Fludrocortisone in High-risk Patients Undergoing Cardiac Surgery
NCT07037043Phase 3Recruiting
- Sponsor
- CHU Amiens-Picardie
- Start
- Apr 2025
- Primary completion
- May 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in inflammation comparing hydrocortisone plus fludrocortisone with placebo (2 arms). Primary endpoints: Variation of acute kidney injury occurrence at 7 days, Variation of postoperative pulmonary complication occurrence at 7 days and 1 more. Started Apr 2025; status: recruiting.
02
Drugs
hydrocortisonefludrocortisone
03
Conditions
inflammation
Beyond the preview
Go deeper on NCT07037043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07037043.